NeuroOne Medical Technologies Corp (NMTC) Beta Value: Understanding the Market Risk

The 36-month beta value for NMTC is also noteworthy at 1.05. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for NMTC is 22.03M, and at present, short sellers hold a 0.71% of that float. The average trading volume of NMTC on April 03, 2024 was 179.74K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

NMTC) stock’s latest price update

NeuroOne Medical Technologies Corp (NASDAQ: NMTC)’s stock price has plunge by 5.89relation to previous closing price of 1.23. Nevertheless, the company has seen a 12.28% surge in its stock price over the last five trading sessions. Seeking Alpha reported 2024-02-13 that NeuroOne Medical Technologies Corporation (NMTC) Q1 2024 Earnings Call Transcript

NMTC’s Market Performance

NMTC’s stock has risen by 12.28% in the past week, with a monthly drop of -5.62% and a quarterly drop of -19.60%. The volatility ratio for the week is 12.17% while the volatility levels for the last 30 days are 11.54% for NeuroOne Medical Technologies Corp The simple moving average for the last 20 days is 11.75% for NMTC stock, with a simple moving average of 8.88% for the last 200 days.

Analysts’ Opinion of NMTC

Many brokerage firms have already submitted their reports for NMTC stocks, with Craig Hallum repeating the rating for NMTC by listing it as a “Hold.” The predicted price for NMTC in the upcoming period, according to Craig Hallum is $2 based on the research report published on March 29, 2022 of the previous year 2022.

NMTC Trading at 7.71% from the 50-Day Moving Average

After a stumble in the market that brought NMTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.78% of loss for the given period.

Volatility was left at 11.54%, however, over the last 30 days, the volatility rate increased by 12.17%, as shares sank -1.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.08% lower at present.

During the last 5 trading sessions, NMTC rose by +3.70%, which changed the moving average for the period of 200-days by +1.08% in comparison to the 20-day moving average, which settled at $1.1646. In addition, NeuroOne Medical Technologies Corp saw -17.57% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NMTC starting from Christianson Mark, who sale 31,445 shares at the price of $1.46 back on Dec 27 ’23. After this action, Christianson Mark now owns 300,594 shares of NeuroOne Medical Technologies Corp, valued at $45,859 using the latest closing price.

Christianson Mark, the Business Development Director of NeuroOne Medical Technologies Corp, sale 6,848 shares at $1.35 during a trade that took place back on Dec 26 ’23, which means that Christianson Mark is holding 332,039 shares at $9,269 based on the most recent closing price.

Stock Fundamentals for NMTC

Current profitability levels for the company are sitting at:

  • -4.82 for the present operating margin
  • 0.26 for the gross margin

The net margin for NeuroOne Medical Technologies Corp stands at -4.78. The total capital return value is set at -3.05. Equity return is now at value -214.01, with -174.02 for asset returns.

Based on NeuroOne Medical Technologies Corp (NMTC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -85.9.

Currently, EBITDA for the company is -11.76 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 10.71. The receivables turnover for the company is 5.18for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.68.


In summary, NeuroOne Medical Technologies Corp (NMTC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts